LQDA: $1.2M Put Bet Signals Someone's Bracing for a Major Crash!
January 9, 2026 | Unusual Activity Detected
The Quick Take
Someone just dropped $1.2 MILLION on puts betting LQDA crashes 32% below its current price! With a Vol/OI ratio of nearly 88x average - this is the kind of unusual activity that happens maybe a few times a year. Either a whale is hedging a massive long position ahead of the JPMorgan Conference and patent litigation news, or they know something about Liquidia's upcoming catalysts that we don't.
Company Overview
Liquidia Corporation (NASDAQ: LQDA) is a mid-cap biopharmaceutical company focused on developing innovative therapies for respiratory and vascular diseases using its proprietary PRINT Technology:
- Market Cap: $2.73-2.76 billion
- Current Price: $36.95 (up 203% over the past year)
- 52-Week Range: $11.26 - $36.41
- Key Product: YUTREPIA (treprostinil) - FDA-approved May 23, 2025 for PAH and PH-ILD; first and only prostacyclin dry-powder formulation
- Pipeline: L606 extended-release treprostinil formulation, Generic Treprostinil Injection
- Headquarters: Morrisville, North Carolina
LQDA is experiencing a transformational year following FDA approval of YUTREPIA in May 2025. The company just announced preliminary FY 2025 YUTREPIA net product sales of $148.3M with 2,800+ unique patient prescriptions and an 85% conversion rate from prescription to patient start. However, the stock recently pulled back 11% after Needham removed it from their 2026 Conviction List, and patent litigation with United Therapeutics presents binary risk/reward scenarios.
The Option Flow Breakdown
The Tape (January 9, 2026 @ 10:44:34)
| Time | Symbol | Side | Buy/Sell | Type | Expiration | Premium | Strike | Volume | OI | Z-Score | Spot | Option Price |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10:44:34 | LQDA | BID | BUY | PUT $25 | 2026-02-20 | $1.2M | $25 | 5K | 57 | 87.72 | $36.95 | $2.40 |
What This Actually Means
Real talk: This is NOT your neighbor Bob's Robinhood account. Here's why this trade is screaming for attention:
Key Trade Statistics:
- Strike is 32.3% OUT-OF-THE-MONEY - The $25 strike is way below the current price of $36.95
- Vol/OI of 87.72x is EXTREMELY HIGH - This is the kind of unusual activity you might see a few times per year
- 42 days to expiration - Gives time for earnings, JPMorgan conference, and patent litigation to play out
- $1.2M on the line - This is serious money, not a gamble
- Notional exposure: 500,000 shares worth ~$18.5M at current prices
Translation for regular folks: Someone is either:
- Hedging a massive long position - They own millions in LQDA stock and want insurance
- Betting on a catastrophic drop - They see a crash coming (patent lawsuit loss? earnings miss?)
- Playing the volatility - Expecting wild swings around upcoming catalysts
The timing is suspicious - just 5 days before the JPMorgan Healthcare Conference and weeks before earnings.
Unusual Score: EXTREMELY UNUSUAL (Z-score 87.72)
The 87.72x Vol/OI ratio is extraordinary - this happens a few times per year at most. This kind of positioning signals sophisticated institutional activity, not retail speculation. Someone is making a significant directional bet or massive hedge ahead of binary catalysts.
Technical Setup / Chart Check-Up
YTD Performance Chart
LQDA has been on a wild ride! The stock is up a massive 203% over the past year, riding the YUTREPIA FDA approval wave from May 2025. However, it's pulled back 11% in the past month after Needham removed it from their 2026 Conviction List.
Key observations:
- 52-week high of $36.41 hit in December 2025
- Recent pullback from highs suggests profit-taking
- Still trading near multi-year highs despite the dip
Gamma-Based Support & Resistance Analysis
Current Price: $36.95
Based on the gamma exposure data, here's where the action is:
Support Levels (Put Gamma Below Price):
| Strike | Distance | Net GEX | Total GEX | Notes |
|---|---|---|---|---|
| $35.50 | -3.9% | $78.5K | $79.7K | Immediate support floor |
| $35.00 | -5.3% | $1.57M | $1.64M | MASSIVE - Heavy gamma concentration, expect bounce here |
| $32.50 | -12% | -$345K | $640K | Net negative gamma - could accelerate selling |
| $30.00 | -18.8% | $319K | $1.68M | Major psychological & gamma support |
Resistance Levels (Call Gamma Above Price):
| Strike | Distance | Net GEX | Total GEX | Notes |
|---|---|---|---|---|
| $37.50 | +1.5% | $925K | $951K | First resistance ceiling above |
| $40.00 | +8.3% | $4.52M | $4.53M | BIGGEST gamma wall - hard to break |
| $42.50 | +15% | $491K | $496K | Extended bull target |
Gamma Bias: BULLISH
Total call gamma ($10.28M) significantly outweighs put gamma ($2.51M), suggesting market makers are positioned for upside. However, that $1.2M put bet is a contrarian warning sign!
Implied Move Analysis
The options market is pricing in MASSIVE volatility:
| Timeframe | Expiry | Implied Move | Range |
|---|---|---|---|
| Weekly | Jan 16 | ±15.4% | $31.56 - $43.03 |
| Feb OPEX | Feb 20 | ±45%* | $20.42 - $54.17 |
| Triple Witch | Mar 20 | ±69.2% | $11.50 - $63.09 |
The Feb 20 expiration is exactly where this PUT $25 trade sits!
Key insight: The $25 strike put would be in-the-money if LQDA drops to the lower implied move range of $20.42 by Feb expiration. The market is pricing in the possibility of a 45% swing - and someone just bet $1.2M on the downside.
Catalysts
Recent Catalysts (Already Happened)
| Date | Event | Impact |
|---|---|---|
| Jan 9, 2026 | Preliminary FY 2025 Results Released | YUTREPIA sales of $148.3M, Q4 sales of ~$90.1M |
| Jan 2, 2026 | Heavy Put Activity Detected | 15,696 puts traded (56% above average) |
| Dec 2025 | Needham Removed from Conviction List | Stock dropped 11% in a month |
| Nov 3, 2025 | Q3 Earnings Beat | Revenue beat by 188%, first positive EBITDA |
| May 23, 2025 | FDA Approved YUTREPIA | Transformational approval for PAH treatment |
Upcoming Catalysts (On the Radar)
| Date | Event | Impact Level |
|---|---|---|
| Jan 14, 2026 | JPMorgan Healthcare Conference | HIGH - CEO presenting |
| Jan 16, 2026 | Options Expiration (High Put OI) | MEDIUM |
| Feb 2, 2026 | Q4/FY2025 Earnings Report | HIGH |
| Feb 20, 2026 | This PUT $25 Expires! | THE DATE |
| Q1-Q2 2026 | Patent Litigation Decisions | VERY HIGH - Binary outcome! |
| H1 2026 | L606 ASCENT Study Completion | MEDIUM |
The Big Picture: This $1.2M PUT $25 is timed perfectly to capture the JPMorgan conference, earnings, AND potentially a patent litigation decision. Smart money knows something's brewing.
Price Targets & Probabilities
Based on gamma levels, implied move data, and catalyst analysis:
Bull Case: $40-$42.50 (35% probability)
How we get there:
- JPMorgan conference delivers bullish 2026 guidance
- Patent litigation ruling favors Liquidia
- YUTREPIA prescription growth accelerates
- Gamma resistance at $40 gets broken
Gamma signal: $40 strike has the BIGGEST call gamma ($4.52M net) - if this breaks, momentum could carry to $42.50
Base Case: $33-$37 (45% probability)
The consolidation scenario:
- Stock chops between gamma support ($35) and resistance ($37.50)
- No major surprises from JPMorgan or earnings
- Patent litigation remains uncertain
- Put buyer loses most of their premium
Gamma signal: Strong gamma concentration at $35 creates a floor, while $37.50 acts as a ceiling
Bear Case: $25-$30 (20% probability)
How we get there:
- Adverse patent litigation ruling threatens YUTREPIA sales
- Earnings miss or weak 2026 guidance
- Competitive pressure from Insmed's TPIP data
- That $1.2M PUT $25 bet pays off massively
Gamma signal: Below $32.50, gamma turns negative (accelerates selling). The implied move suggests $20.42 is possible by Feb 20!
Trading Ideas
Conservative: "The Insurance Policy"
Strategy: Buy protective puts on existing LQDA long positions
- Trade: Buy Feb 20 $32.50 Put
- Cost: ~$2.00-$2.50 per contract ($200-$250 per 100 shares)
- Max Loss: Premium paid
- Why it works: If someone is betting $1.2M on a crash, maybe you should have some insurance too. This protects you through earnings and patent news.
Balanced: "The Wait-and-See Spread"
Strategy: Put Credit Spread (Neutral-Bullish)
- Trade: Sell Feb 20 $30 Put / Buy Feb 20 $25 Put
- Credit: ~$1.00-$1.50 per spread
- Max Profit: Credit received if LQDA stays above $30
- Max Loss: $5 width minus credit = ~$3.50-$4.00
- Why it works: You're betting the whale's $25 put is too aggressive. Even a drop to $30 keeps you profitable.
Aggressive: "The Contrarian Call"
Strategy: Buy Calls Against the Put Flow
- Trade: Buy Feb 20 $40 Call
- Cost: ~$1.50-$2.00 per contract
- Target: $45+ on patent win or earnings blowout
- Why it works: When everyone's buying puts, sometimes the contrarian bet wins. Heavy put activity can actually be bullish if it's all hedging, not directional.
View LQDA Feb 20 $25 Put Option Chart
Risk Factors
Let's be honest about what could go wrong:
-
Patent Litigation is Binary - An adverse ruling on the '782 or '327 patent cases could result in an injunction blocking YUTREPIA sales. Analysts warn this shouldn't be ignored.
-
Stock is Up 200%+ in a Year - Lot of profit-taking potential. The Needham downgrade shows even bulls are getting nervous.
-
Competition Heating Up - Insmed's TPIP data threatens long-term market share. United Therapeutics isn't giving up either.
-
Cash Obligations - $23.8M due to HealthCare Royalty in 2026. Need continued strong sales.
-
That $1.2M Put with 87.7x Vol/OI Knows Something - When someone bets this big on the downside with an EXTREMELY HIGH 87.7x Vol/OI ratio, pay attention. This level of unusual activity happens only a few times per year.
The Bottom Line
Real talk: A $1.2M bet on LQDA crashing to $25 by February 20 is not something to ignore. This is happening right before major catalysts - JPMorgan conference (Jan 14), earnings (Feb 2), and pending patent litigation decisions.
The 87.7x Vol/OI ratio is EXTREMELY UNUSUAL - this kind of positioning happens maybe a few times per year and signals sophisticated institutional activity ahead of binary catalysts.
Here's your action plan:
| Your Stance | What to Do |
|---|---|
| Bullish | Consider protective puts. The gamma is still bullish overall, but this put flow is a warning sign. Maybe take some profits off the table. |
| On the Fence | Wait for JPMorgan conference on Jan 14. CEO's presentation could clarify 2026 outlook. Watch for patent litigation updates. |
| Bearish | The $1.2M PUT $25 buyer might be onto something. Consider put spreads or reducing long exposure before Feb earnings. |
Mark your calendar:
- Jan 14: JPMorgan Conference - big reveal
- Feb 2: Earnings - the main event
- Feb 20: This put expires - moment of truth
The lesson: When a whale drops $1.2M on far OTM puts with an EXTREMELY HIGH 87.7x Vol/OI ratio, either they're hedging something massive or they see a storm coming. Either way, this isn't the time for blind optimism.
View Full LQDA Analysis on Ainvest
About Liquidia Corporation: LQDA is a biopharmaceutical company focused on developing innovative therapies for respiratory and vascular diseases, with its flagship product YUTREPIA (treprostinil inhalation powder) FDA-approved for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Options trading involves substantial risk and is not suitable for all investors. Past performance is not indicative of future results. Always do your own research and consult with a qualified financial advisor before making any investment decisions.
Data as of January 9, 2026